Navigation Links
Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day

SOUTH SAN FRANCISCO, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that it will hold its Third Annual R&D Day on Wednesday, December 5, 2007 from 10:00 a.m. ET / 7:00 a.m. PT to 2:00 p.m. ET / 11:00 a.m. PT in New York. The company will discuss updates to its development pipeline, its collaborations, including those with GSK, BMS and Genentech, and its financial outlook for 2007.


-- George Scangos, PhD, President & Chief Executive Officer of Exelixis,


-- Michael Morrissey, PhD, President of Research & Development of

Exelixis, Inc.

-- Frank Karbe, Executive Vice President & Chief Financial Officer of

Exelixis, Inc.

-- Peter Lamb, PhD, Senior Vice President, Discovery Research & Chief

Scientific Officer of Exelixis, Inc.

-- Gisela Schwab, MD, Senior Vice President and Chief Medical Officer of

Exelixis, Inc.

-- Steven Sherman, MD of MD Anderson Cancer Center

-- Vince Miller, MD of Memorial Sloan-Kettering Cancer Center

The event will be webcast and may be accessed in the Event Calendar page under Investors at

An archive of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on January 4, 2008. Access numbers for this replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international); the replay passcode number is: 21270665.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
2. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Exelixis Announces Closing of Public Offering of Common Stock
5. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
6. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
7. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
8. Exelixis Sells 80% Stake in Artemis to Taconic
9. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
10. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
11. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
Post Your Comments:
(Date:10/10/2017)... ... October 10, 2017 , ... For the second time ... US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. ... US2020. , US2020’s mission is to change the trajectory of STEM education in ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced the ... NIH to develop RealSeq®-SC (Single Cell), expected to be ... small RNAs (including microRNAs) from single cells using NGS ... the need to accelerate development of approaches to analyze ... "New techniques for measuring levels of mRNAs ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
(Date:10/9/2017)... Phoenix, Arizona (PRWEB) , ... October 09, 2017 ... ... of Kindred, a four-tiered line of medical marijuana products targeting the needs of ... production and packaging of Kindred takes place in Phoenix, Arizona. , As operators ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
Breaking Biology News(10 mins):